Promising MND drug helps slow disease progression and benefits patients physically

Scientists believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care, after the results of a Phase 3 clinical trial showed significant physical benefits for patients after 12 months.

from Latest Science News -- ScienceDaily https://ift.tt/2pzxT5j